Brenner M K, Rill D R, Moen R C, Krance R A, Mirro J, Anderson W F, Ihle J N
Department of Hematology/Oncology, St Jude Children's Research Hospital, Memphis, Tennessee 38105.
Lancet. 1993 Jan 9;341(8837):85-6. doi: 10.1016/0140-6736(93)92560-g.
Bone marrow harvested for autologous bone-marrow transplantation may contain residual malignant cells even when it is judged to be in remission. Genetic marking and subsequent detection of these cells in recipients would give useful information about the origin of relapse after transplantation. We transferred the neomycin-resistance gene into bone-marrow cells harvested from children with acute myeloid leukaemia in remission. Two patients have relapsed since reinfusion of the marked cells. In both, the resurgent blast cells contained the neomycin-resistance gene marker; thus, remission marrow can contribute to disease recurrence. This method of tracking malignant cells should enable the development of better marrow purging strategies.
即使经判断处于缓解期，用于自体骨髓移植所采集的骨髓中仍可能含有残留的恶性细胞。对这些细胞进行基因标记并随后在受体中进行检测，将为移植后复发的起源提供有用信息。我们将新霉素抗性基因转入从处于缓解期的急性髓性白血病患儿采集的骨髓细胞中。自回输标记细胞以来，有两名患者复发。在这两名患者中，复发的原始细胞均含有新霉素抗性基因标记；因此，缓解期骨髓可导致疾病复发。这种追踪恶性细胞的方法应能促进更好的骨髓净化策略的开发。
